Desperate move or winning formula: BMS to test hep C drug with sovaldi
This article was originally published in Scrip
Executive Summary
In an attempt to keep up with the fierce competition surrounding new treatments for hepatitis C virus, Bristol-Myers Squibb is testing its in-house, experimental, antiviral drug combination with Gilead Sciences' market leading product Sovaldi (sofosbuvir) in a 4-week dose regimen trial.